eMonarcHER: A phase 3 study of abemaciclib plus standard adjuvant endocrine therapy in patients with HR+, HER2+, node-positive, high-risk early breast cancer.

Authors

null

Sara M. Tolaney

Dana-Farber Cancer Institute, Boston, MA

Sara M. Tolaney , Lesley Fallowfield , Peter A. Kaufman , Eva M. Ciruelos , Mary Corona Gainford , Yi Lu , Karla Hurt , Heather Ann Wasserstrom , Yanyun Chen , Shom Goel

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Adjuvant Therapy

Clinical Trial Registration Number

NCT04752332

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS596)

DOI

10.1200/JCO.2021.39.15_suppl.TPS596

Abstract #

TPS596

Poster Bd #

Online Only

Abstract Disclosures